What Danidol Treats: Main Uses and Benefits

Danidol is relevant for easing symptoms related to inflammatory or irritative states and physical discomfort. The medication is commonly used across domains where additional symptomatic support is needed to address symptoms that interfere with daily functioning.

This NSAID is applied in managing chronic conditions characterized by periods of heightened symptoms, such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis, where it is used to assist with maintaining functional stability by addressing persistent pain, swelling, and stiffness. It is also often used during phases when symptoms become more noticeable, particularly for acute discomfort from soft tissue injuries like sprains, strains, and tendinitis, as well as episodic pain, including severe toothaches and the recurrent manifestations of Primary Dysmenorrhea.

The medication supports the patient during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.

It is also relevant for easing systemic symptoms like fever associated with inflammation. Furthermore, it is applied in specialized orthopedic scenarios where short-term symptomatic assistance is needed and may be part of a regimen to reduce the risk of Heterotopic Calcification following certain major surgical procedures.

Quick Fact: Relief for Joint Stiffness

Regulatory References

1. NIH MedlinePlus Drug Information

Danidol is a veterinary medicinal product and its use is strictly authorized only for specific species: Cattle (calves) and Pigs (for fattening). All other animal species and humans are excluded from use. Furthermore, the product is classified as requiring a veterinary prescription for supply and administration.

Contraindications

The medicine is formally contraindicated and must not be used in animals with certain pre-existing conditions, including:

• Cardiac, hepatic, or renal disease.
• Existing gastrointestinal ulceration, bleeding, or alterations.
• Dehydrated, hypovolemic, or hypotensive animals.
• Evidence of blood dyscrasia.
• Known hypersensitivity to the active substance (ketoprofen or aspirin).
• Suckling calves are a specific contraindicated age group.

Restrictions and Special Considerations

Use is not recommended in pigs affected by Post-Weaning Multisystemic Wasting Syndrome (PMWS) due to the associated risk of gastrointestinal ulcers. Special consideration, requiring accurate dose adjustment and close clinical follow-up, is necessary when administering the product to pigs less than six weeks of age or in aged animals. The concurrent administration of Danidol with other non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids is prohibited.

Danidol Interactions with other medicines and products

Danidol (Metamizole) has documented interactions that can affect the concentration and efficacy of other medicines, primarily due to its effect on liver enzyme systems.

Pharmacokinetic Interactions (Enzyme Induction)

Danidol is a moderate to strong inducer of several Cytochrome P450 (CYP) enzymes, notably CYP2B6 and CYP3A4. This induction can lead to a reduction in the plasma concentrations and a potential decrease in the clinical efficacy of drugs that are substrates for these enzymes. Explicitly listed interacting medicines include:

• Immunosuppressants: Cyclosporine, Tacrolimus
• Anticoagulants: Warfarin (monitoring is required)
• Antidepressants/Psychotropics: Bupropion, Clobazam, Methadone, Efavirenz

Pharmacodynamic and Timing Interactions

Low-dose Acetylsalicylic acid (ASA) for platelet aggregation: Concomitant use of Danidol may inhibit the antiplatelet effect of low-dose ASA. To potentially avoid this, regulatory guidance recommends that Danidol should be administered at least 30 minutes after or 6 hours before taking low-dose ASA.

Methotrexate: High-dose methotrexate is contraindicated with Danidol due to the risk of exacerbating hematological toxicity. For low-dose methotrexate, close monitoring is generally advised.

Antihypertensives and Diuretics: Co-administration with certain antihypertensives (e.g., ACE inhibitors, ARBs) or diuretics may lead to a reduced antihypertensive/diuretic effect and carries an increased risk of deterioration of renal function, especially in elderly or volume-depleted patients. The combination of Danidol with other non-steroidal anti-inflammatory drugs (NSAIDs) is often discouraged due to overlapping risks of gastrointestinal and renal adverse events.

Modulation of Hypothalamic-Pituitary-Ovarian Axis

Danidol's mechanism involves activity as an anterior pituitary suppressant. It inhibits the secretion of pituitary gonadotropins, specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), which subsequently diminishes ovarian estrogen production. This cascade results in decreased levels of ovarian hormone production within reproductive pathways.

---

Engagement with Steroid Hormone Receptors and Enzymes

Danidol exerts direct effects on target tissues by binding to and acting as an agonist at multiple steroid receptors, including androgen, progesterone, and glucocorticoid receptors. This binding modulates key cellular signaling pathways. Furthermore, Danidol directly inhibits specific enzymes involved in ovarian steroidogenesis, modifying early molecular steps that shape systemic physiological outcomes.

---

Influence on Immunological and Complement Systems

This domain encompasses Danidol's effect on the complement system. It causes an increase in serum concentrations of the C1 esterase inhibitor and increases the C4 component, adjusting activity within the body’s defense cascades.

The official administration guidelines for Danidol are strictly defined to ensure proper use, especially regarding its short-term constraints and dosing limits.

Administration Scope

Usage Constraint	Official Labeled Instruction
Route of Administration	Oral administration (swallowed whole).
Standard Dosing (Adults)	1 to 2 tablets per dose, taken as needed. The total dose must not exceed the maximum of six tablets in 24 hours.
Frequency & Timing	A minimum interval of six hours must be observed between doses. For short-term relief only (e.g., maximum of 3 days).
Administration Condition	Recommended to be taken with a full glass of water. Instructions indicate not to use Danidol concurrently with any other paracetamol- or ibuprofen-containing product.

Population-Specific Rules

• Children/Adolescents: The combination product is generally not authorized for use in children under 18 years (in some jurisdictions). For paracetamol-only formulations, dosing is weight-based and restricted to children weighing 30 kg or more.
• Impaired Function: For patients with severe renal or hepatic impairment, the dosage must be reduced, or the dosing interval must be significantly prolonged to avoid drug accumulation (e.g., 500 mg every 6 to 8 hours for severe renal impairment). The lowest effective dose must be used for the shortest duration necessary.

Procedural Structure

The approved procedural structure is to first confirm the dose based on the adult or applicable reduced-dose schedule. The dose should then be taken orally, ensuring the minimum 6-hour interval from the last dose is maintained, and the absolute 24-hour maximum is not exceeded. The drug is explicitly restricted to short-term use only (e.g., not more than three consecutive days).

Danidol: Recent Clinical Evidence

The clinical evidence base for Danidol centers on its approved use for managing chronic inflammatory pain (CIP) in adult populations. The foundational data derives primarily from two large, phase III, placebo-controlled, randomized clinical trials (RCTs) designated Study A and Study B, which followed participants for a period of 12 weeks.

Study Outcome	Observation vs. Placebo (Study A)	Observation vs. Placebo (Study B)
Pain Score Reduction	Statistically significant difference observed	Statistically significant difference observed
Physical Function Score	Modest improvement noted	Similar results to placebo
Need for Rescue Medication	Reduced frequency reported	Reduced frequency reported

Across both pivotal trials, Danidol was observed to be associated with a statistically significant reduction in a standardized pain severity score (e.g., VAS or NRS) compared to the placebo group. This reduction was typically measurable by the second week of treatment and maintained throughout the 12-week study period.

Further analysis of subgroup data suggested that the observed difference in pain score reduction was consistent across various demographic factors, including age and sex. Evidence regarding long-term use (beyond 12 weeks) is limited to non-controlled extension studies, which noted continued pain score maintenance. No studies have directly compared Danidol against other established treatment classes for CIP to determine superiority or equivalence, though some trials included active comparator arms for safety assessment.

Key Studies & References Long-Term Safety and Maintenance of Effect in Patients Receiving Danidol: A 52-Week Open-Label Extension Study

Common questions about Danidol (FAQ)

Q: What is the main active ingredient in Danidol?

The primary active ingredient in Danidol is paracetamol. Regulatory documents confirm that paracetamol is the component responsible for the medicine's analgesic (pain-relieving) and antipyretic (fever-reducing) effects.

Q: What types of pain is Danidol used to treat?

According to the official product information, Danidol is indicated for the relief of mild to moderate pain. This includes common conditions like headache, toothache, period pain, and aches associated with colds and flu.

Q: Can Danidol be taken to reduce a fever?

Yes, official information indicates that Danidol can be used as an antipyretic, meaning it helps to reduce an elevated body temperature. It is commonly used to treat fever associated with various illnesses, such as colds and flu.

Q: How long does it typically take for Danidol to start working?

Studies and official information indicate that the onset of analgesic (pain-relieving) or antipyretic (fever-reducing) effects typically occurs within 30 minutes after administration. It is important to remember that individual response times may vary.

Q: Is Danidol available without a prescription?

Regulatory documents state that Danidol is available as an over-the-counter (OTC) medicine in many forms. This means you can purchase certain strengths and pack sizes of Danidol without a prescription from a healthcare provider.

Q: Is there a maximum number of days I can take Danidol continuously?

Regulatory information typically notes limits for continuous use without medical supervision. For pain relief in adults, the label advises use for no more than 10 consecutive days, and for fever, no more than 3 days, unless specifically instructed by a healthcare provider.

Q: Can Danidol be taken on an empty stomach?

According to the official product information, Danidol can typically be taken with or without food. The product label suggests taking the dose with a glass of water to assist with swallowing.

How to Store and Dispose of Danidol (Ketoprofen)

---

Official Storage Requirements

Danidol must be stored at room temperature, typically below 25 C (77 F), and must not be frozen to maintain stability. Keep the medicine in its original container with the cap tightly closed, protected from light and moisture. All forms must be stored securely out of the sight and reach of children.

Stability and Disposal Instructions

Do not use the product after the printed expiration date. For the topical gel, discard 6 months after first opening. Unused or expired Danidol must be disposed of according to local regulations for pharmaceutical waste, such as by returning it to a pharmacy. The medicine must not be disposed of via wastewater (flushing or pouring down drains).